Tratamento da papilomatose canina com Propionibacterium acnes

Megid, Jane; Dias, Juliana Tedesco; Aguiar, Daniel Moura de; Júnior, G. Nardi; Silva, W.B.; Ribeiro, Márcio Garcia

doi:10.1590/s0102-09352001000500011

Cited by 9 publications

(6 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…41,42 Immunomodulating drugs that have been suggested for use against papilloma infections include azithromycin, 43 interferon a-2b, 44 and P acne. 45 Table 4 summarizes mechanisms of some of the immunotherapies suggested for the treatment of oral papillomas. 43,44,45,73,74 Clinicians must use their judgment and consider the risks and benefits of implementing off-label drug treatments.…”

Section: Discussionmentioning

confidence: 99%

“…45 Table 4 summarizes mechanisms of some of the immunotherapies suggested for the treatment of oral papillomas. 43,44,45,73,74 Clinicians must use their judgment and consider the risks and benefits of implementing off-label drug treatments. It should also be remembered that of the potential treatments suggested for oral papillomas, only azithromycin, has been evaluated in a controlled study.…”

Section: Discussionmentioning

confidence: 99%

“…41,42 Immunomodulatory therapy may be considered if the patient's immunity is compromised. [43][44][45] The use of therapeutic vaccines for Canine papillomavirus (CPV) infections is documented in the literature. 40 However, to the authors' knowledge, no appropriate controlled studies have been performed, and since VPs are self-resolving, there is still some uncertainty regarding whether therapeutic vaccines are efficacious.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Malignant Transformation of a Canine Papillomavirus Type 1-Induced Persistent Oral Papilloma in a 3-Year-Old Dog

Ibarra¹,

Legendre²,

Munday

2018

J Vet Dent

View full text Add to dashboard Cite

This case report describes a rare case of a persistent canine papillomavirus type 1 (CPV-1)-induced oral papilloma that underwent malignant transformation into an oral squamous cell carcinoma (OSCC) in a 3-year-old Labrador retriever cross. Initially, the patient had multiple and multifocal verrucous lesions populating the oral cavity exclusively. The papillomas persisted despite multiple surgical ablations, azithromycin, interferon α-2b, alternative medicines, and off-label drug use of an immunostimulant. After 1 year and 6 months, an aggressive lesion developed at the level of the left mandibular first molar (309) and progressed to a well-differentiated invasive OSCC. The presence of CPV-1 DNA in the OSCC, and the known oncogenic abilities of CPV-1, suggests that this virus might have played a significant role in the emergence of the OSCC that ultimately led to the patient's euthanasia due to poor quality of life. This is the first well-documented case where OSCC has developed from an oral papilloma caused by CPV-1 in which the presence of coinfection by another papillomavirus was excluded by multiple polymerase chain reaction tests using various primers.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Malignant Transformation of a Canine Papillomavirus Type 1-Induced Persistent Oral Papilloma in a 3-Year-Old Dog

Ibarra¹,

Legendre²,

Munday

2018

J Vet Dent

View full text Add to dashboard Cite

show abstract

“…Propionium bacterium parvum , also known as Propionibacterium acnes or Coryneobacterium parvum is a gram-positive, pleomorphic, strictly anaerobic bacterium. [ 80 81 82 ] It has a potent stimulant effect on the reticuloendothelial system and has been used in recent years as an antibacterial and adjuvant immune stimulant to chemotherapy in numerous tumors. [ 83 84 85 ] It can be administered parenterally or topically.…”

Section: Introductionmentioning

confidence: 99%

Immunomodulators in warts: Unexplored or ineffective?

2015

View full text Add to dashboard Cite

Cutaneous warts are known to be recurrent and often resistant to therapy. Resistant warts may reflect a localized or systemic cell mediated immune (CMI) deficiency to HPV. Many modalities of treatment are in use; most of the provider-administered therapies are destructive and cause scarring, such as cryotherapy, chemical cauterisation, curettage, electrodessication and laser removal. Most patient-applied agents like podophyllotoxin have the risk of application-site reactions and recurrence. Thus immunotherapy is a promising modality which could lead to resolution of warts without any physical changes or scarring and in addition would augment the host response against the causative agent, thereby leading to complete resolution and decreased recurrences. Immunomodulators can be administered systemically, intralesionally or intradermally, and topically. A few agents have been tried and studied extensively such as cimetidine and interferons; others are new on the horizon, such as Echinacea, green tea catechins and quadrivalent HPV vaccine, and their efficacy is yet to be completely established. Though some like levamisole have shown no efficacy as monotherapy and are now used only in combination, other more recent agents require large and long term randomized placebo-controlled trials to clearly establish their efficacy or lack of it. In this review, we focus on the immunomodulators that have been used for the treatment of warts and the studies that have been conducted on them.

show abstract

“…Megid et al 45 dealing with dogs in veterinary setting, affected by oral papillomatosis, a virus‐induced pathology of the mouth, at different ages achieved complete regression after five average weekly injections of C. parvum , locally delivered 45 . The same author (2002) examined in the rabies infected swiss mice the lethality and distribution of the virus copies comparing the plain vaccination versus vaccination + C. parvum 46 .…”

Section: Introductionmentioning

confidence: 99%

The long‐standing history of Corynebacterium parvum, immunity, and viruses

Palmieri

Vadalà²,

Roncati

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

We report a review of all the experimental and clinical studies performed in the last 60 years on the antiviral activity of inactivated Corynebacterium parvum (Cutibacterium acnes). This bacterium has been originally investigated and used for its oncolytic properties linked to immunomodulating activity, but the interest to successfully prevent and treat bacterial, fungal, and viral infections and lethality, uprising the innate immunity barriers produced many experimental models and very few clinical studies. The dramatic defenseless situation due to impending CoViD-19 pandemic claims to exhume and highlight this aspecific strategy in preventive and therapeutic settings; as a matter of fact, no new or mutated virus can potentially escape to this strong innate immune surveillance strengthened by adequate C. parvum protocols.

show abstract

Tratamento da papilomatose canina com Propionibacterium acnes

Cited by 9 publications

References 2 publications

Malignant Transformation of a Canine Papillomavirus Type 1-Induced Persistent Oral Papilloma in a 3-Year-Old Dog

Malignant Transformation of a Canine Papillomavirus Type 1-Induced Persistent Oral Papilloma in a 3-Year-Old Dog

Immunomodulators in warts: Unexplored or ineffective?

The long‐standing history of Corynebacterium parvum, immunity, and viruses

Contact Info

Product

Resources

About